Diffuse Large B-cell Lymphoma-Treatment Failure, Recovery and COVID-19: A Case Report
Diffuse Large B-cell Lymphoma (DLBCL) is the most common form of non-hodgkin lymphoma, involving multiple organ system including lymph node, bone marrow, spleen etc. Among overall cases of DLBCL, 40% are extranodal in origin and stomach being the most common site. While most of the (60%) are not dia...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
JCDR Research and Publications Private Limited
2022-05-01
|
| Series: | Journal of Clinical and Diagnostic Research |
| Subjects: | |
| Online Access: | https://www.jcdr.net/articles/PDF/16309/55715_CE[Ra1]_F[SH]_PF1(AG_SS)_PFA_PB(AG_KM)_PN(KM).pdf |
| _version_ | 1828035833357139968 |
|---|---|
| author | Ponvijaya M Yadav Rupesh S Parati Vijayshree S Gokhale Dhiral R Mahajan Atiullah Imran Malik |
| author_facet | Ponvijaya M Yadav Rupesh S Parati Vijayshree S Gokhale Dhiral R Mahajan Atiullah Imran Malik |
| author_sort | Ponvijaya M Yadav |
| collection | DOAJ |
| description | Diffuse Large B-cell Lymphoma (DLBCL) is the most common form of non-hodgkin lymphoma, involving multiple organ system including lymph node, bone marrow, spleen etc. Among overall cases of DLBCL, 40% are extranodal in origin and stomach being the most common site. While most of the (60%) are not diagnosed until the disease reach stage 3 or 4. While in the present case of a 65-year-old female, patient had predominant involvement of neck lymph nodes. Following the final diagnosis, patient was given first line treatment in the form of Rituximab, Cyclophosphamide, Hydroxydaunorubicin hydrochloride (doxorubicin hydrochloride), vincristine (Oncovin) and Prednisone (R-CHOP) regimen, to which patient didn’t respond and further the patient was given Rituximab, Ifosfamide, Carboplatin, and Etoposide (R-ICE) regimen, to which patient responded quickly. With Coronavirus Disease 2019 (COVID-19) pandemic, the patient encountered infection with its associated complication. The following case report is all about the timely management of DLBCL and patient’s survival with COVID-19 and its related complication. Haematological malignancy such as lymphomas, leukaemias, myelomas cause severe myelosuppression and lymphodepletion increasing the risk for development of COVID-19. Studies have shown that patients with malignancy had an estimated two-fold increased risk of contracting Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) than the general population. The survival rates strongly depend on COVID-19 stage and other factors such as immune (neutropenia) status and systemic inflammation. |
| first_indexed | 2024-04-10T15:51:07Z |
| format | Article |
| id | doaj.art-d5978bb88e364d38abd32b10089cb6bb |
| institution | Directory Open Access Journal |
| issn | 2249-782X 0973-709X |
| language | English |
| last_indexed | 2024-04-10T15:51:07Z |
| publishDate | 2022-05-01 |
| publisher | JCDR Research and Publications Private Limited |
| record_format | Article |
| series | Journal of Clinical and Diagnostic Research |
| spelling | doaj.art-d5978bb88e364d38abd32b10089cb6bb2023-02-11T10:47:43ZengJCDR Research and Publications Private LimitedJournal of Clinical and Diagnostic Research2249-782X0973-709X2022-05-01165OD01OD0410.7860/JCDR/2022/55715.16309Diffuse Large B-cell Lymphoma-Treatment Failure, Recovery and COVID-19: A Case ReportPonvijaya M Yadav0Rupesh S Parati1Vijayshree S Gokhale2Dhiral R Mahajan3Atiullah Imran Malik4Resident, Department of General Medicine, Dr. D.Y. Patil Medical College, Pimpri, Pune, Maharashtra, India.Resident, Department of General Medicine, Dr. D.Y. Patil Medical College, Pimpri, Pune, Maharashtra, India.Professor, Department of General Medicine, Dr. D.Y. Patil Medical College, Pimpri, Pune, Maharashtra, India.Resident, Department of General Medicine, Dr. D.Y. Patil Medical College, Pimpri, Pune, Maharashtra, India.Senior Resident, Department of General Medicine, Dr. D.Y. Patil Medical College, Pimpri, Pune, Maharashtra, India.Diffuse Large B-cell Lymphoma (DLBCL) is the most common form of non-hodgkin lymphoma, involving multiple organ system including lymph node, bone marrow, spleen etc. Among overall cases of DLBCL, 40% are extranodal in origin and stomach being the most common site. While most of the (60%) are not diagnosed until the disease reach stage 3 or 4. While in the present case of a 65-year-old female, patient had predominant involvement of neck lymph nodes. Following the final diagnosis, patient was given first line treatment in the form of Rituximab, Cyclophosphamide, Hydroxydaunorubicin hydrochloride (doxorubicin hydrochloride), vincristine (Oncovin) and Prednisone (R-CHOP) regimen, to which patient didn’t respond and further the patient was given Rituximab, Ifosfamide, Carboplatin, and Etoposide (R-ICE) regimen, to which patient responded quickly. With Coronavirus Disease 2019 (COVID-19) pandemic, the patient encountered infection with its associated complication. The following case report is all about the timely management of DLBCL and patient’s survival with COVID-19 and its related complication. Haematological malignancy such as lymphomas, leukaemias, myelomas cause severe myelosuppression and lymphodepletion increasing the risk for development of COVID-19. Studies have shown that patients with malignancy had an estimated two-fold increased risk of contracting Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) than the general population. The survival rates strongly depend on COVID-19 stage and other factors such as immune (neutropenia) status and systemic inflammation.https://www.jcdr.net/articles/PDF/16309/55715_CE[Ra1]_F[SH]_PF1(AG_SS)_PFA_PB(AG_KM)_PN(KM).pdfchemotherapycoronavirus disease-2019haematological malignancylymphomanon-hodgkin lymphoma |
| spellingShingle | Ponvijaya M Yadav Rupesh S Parati Vijayshree S Gokhale Dhiral R Mahajan Atiullah Imran Malik Diffuse Large B-cell Lymphoma-Treatment Failure, Recovery and COVID-19: A Case Report Journal of Clinical and Diagnostic Research chemotherapy coronavirus disease-2019 haematological malignancy lymphoma non-hodgkin lymphoma |
| title | Diffuse Large B-cell Lymphoma-Treatment Failure, Recovery and COVID-19: A Case Report |
| title_full | Diffuse Large B-cell Lymphoma-Treatment Failure, Recovery and COVID-19: A Case Report |
| title_fullStr | Diffuse Large B-cell Lymphoma-Treatment Failure, Recovery and COVID-19: A Case Report |
| title_full_unstemmed | Diffuse Large B-cell Lymphoma-Treatment Failure, Recovery and COVID-19: A Case Report |
| title_short | Diffuse Large B-cell Lymphoma-Treatment Failure, Recovery and COVID-19: A Case Report |
| title_sort | diffuse large b cell lymphoma treatment failure recovery and covid 19 a case report |
| topic | chemotherapy coronavirus disease-2019 haematological malignancy lymphoma non-hodgkin lymphoma |
| url | https://www.jcdr.net/articles/PDF/16309/55715_CE[Ra1]_F[SH]_PF1(AG_SS)_PFA_PB(AG_KM)_PN(KM).pdf |
| work_keys_str_mv | AT ponvijayamyadav diffuselargebcelllymphomatreatmentfailurerecoveryandcovid19acasereport AT rupeshsparati diffuselargebcelllymphomatreatmentfailurerecoveryandcovid19acasereport AT vijayshreesgokhale diffuselargebcelllymphomatreatmentfailurerecoveryandcovid19acasereport AT dhiralrmahajan diffuselargebcelllymphomatreatmentfailurerecoveryandcovid19acasereport AT atiullahimranmalik diffuselargebcelllymphomatreatmentfailurerecoveryandcovid19acasereport |